Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Canopy Growth Corporation (CGC) Stock Forecast & Price Prediction Canada | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic
$1.02
-0.02 (-1.92%)Did CGC Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Canopy Growth is one of their latest high-conviction picks.
Based on our analysis of 9 Wall Street analysts, CGC has a neutral consensus with a median price target of $1.81 (ranging from $1.81 to $1.81). The overall analyst rating is Buy (6.0/10). Currently trading at $1.02, the median forecast implies a 77.2% upside. This outlook is supported by 1 Buy, 4 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for CGC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | Benchmark | Mike Hickey | Hold | Upgrade | $N/A |
| Mar 27, 2025 | Zuanic & Associates | Pablo Zuanic | Neutral | Initiates | $N/A |
| Jul 9, 2024 | Piper Sandler | Michael Lavery | Underweight | Maintains | $2.00 |
| Sep 15, 2023 | B of A Securities | Lisa Lewandowski | Underperform | Maintains | $0.66 |
| Jun 12, 2023 | CIBC | John Zamparo | Underperformer | Maintains | $0.50 |
| May 2, 2023 | Piper Sandler | Michael Lavery | Underweight | Maintains | $1.00 |
| Feb 17, 2023 | Cantor Fitzgerald | Pablo Zuanic | Neutral | Maintains | $3.20 |
| Nov 7, 2022 | Cantor Fitzgerald | Pablo Zuanic | Neutral | Maintains | $3.30 |
| Nov 2, 2022 | Bernstein | Nadine Sarwat | Underperform | Initiates | $1.50 |
| Oct 26, 2022 | Cantor Fitzgerald | Pablo Zuanic | Neutral | Maintains | $3.05 |
| Sep 30, 2022 | Barclays | Gaurav Jain | Underweight | Maintains | $2.00 |
| Aug 8, 2022 | Piper Sandler | Michael Lavery | Underweight | Maintains | $2.50 |
| Jun 30, 2022 | Piper Sandler | Michael Lavery | Underweight | Maintains | $3.00 |
| Jun 8, 2022 | Barclays | Gaurav Jain | Underweight | Maintains | $3.50 |
| May 31, 2022 | Piper Sandler | Michael Lavery | Underweight | Maintains | $4.00 |
| Mar 22, 2022 | Barclays | Underweight | Downgrade | $N/A | |
| Mar 1, 2022 | Barclays | Gaurav Jain | Equal-Weight | Maintains | $9.00 |
| Feb 18, 2022 | Cantor Fitzgerald | Pablo Zuanic | Neutral | Maintains | $11.00 |
| Dec 22, 2021 | B of A Securities | Lisa Lewandowski | Underperform | Downgrade | $10.00 |
| Dec 20, 2021 | Piper Sandler | Michael Lavery | Underweight | Downgrade | $7.00 |
The following stocks are similar to Canopy Growth based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Canopy Growth Corporation has a market capitalization of $424.35M with a P/E ratio of -0.2x. The company generates $204.82M in trailing twelve-month revenue with a -117.3% profit margin.
Revenue growth is -0.3% quarter-over-quarter, while maintaining an operating margin of -17.6% and return on equity of -48.5%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Produces and distributes cannabis and related products.
The company generates revenue through the production, distribution, and sale of a wide range of cannabis products, including dried flower, extracts, edibles, and vaporizers. It operates in both the adult-use and medical cannabis markets, leveraging its strong presence in Canada and expanding into international markets such as Germany and Australia.
Canopy Growth is headquartered in Smith Falls, Ontario, and was founded in 2009. Its subsidiaries, such as Storz & Bickel, enhance its product offerings by focusing on high-quality, medically certified devices. The company's distribution strategy includes online sales, retail partnerships, and collaboration with provincial retailers, positioning it well within the global cannabis industry.
Healthcare
Drug Manufacturers - Specialty & Generic
960
Mr. Luc Mongeau
Canada
2018
CRLBF faces US pricing pressure despite a Q4 sales beat and a strategic entry into Germany's cannabis market, raising questions about near-term upside.
Zacks.com users are closely monitoring Canopy Growth (CGC), indicating potential interest in the stock's future performance.
Increased interest from Zacks.com users may indicate rising market sentiment or speculation about Canopy Growth, potentially impacting stock performance and investment decisions.
The global cannabis industry is evolving with expanding legalization. Investors are targeting companies poised for long-term growth, particularly Canadian producers.
The evolving global cannabis industry and expanding legalization suggest growth opportunities. Canadian producers' leadership could indicate strong investment potential in this sector.
Canopy Growth, trading at approximately $1 per share, is acquiring another marijuana business through a cash-and-stock deal.
Canopy Growth's acquisition could strengthen its market position and growth potential, impacting its stock value and investor sentiment in the cannabis sector.
Canopy Growth has faced ongoing challenges, showing limited growth while incurring substantial losses and cash burn in recent years.
Canopy Growth's persistent losses and cash burn signal financial instability, raising concerns about its viability and potential impact on stock performance.
Canopy Growth's financial results remain weak, and despite regulatory advancements in the U.S., its future outlook is considered unattractive.
Canopy Growth's poor financial performance and bleak outlook may signal ongoing challenges, potentially affecting stock value and investor confidence in the cannabis sector.
Marijuana stocks, once popular, have seen decreased interest. Canopy Growth, a key company in the sector, continues to face challenges in achieving sustainable profitability.
Struggles of Canopy Growth indicate ongoing challenges in the marijuana sector, suggesting potential volatility and risks for investors in related stocks.
Based on our analysis of 9 Wall Street analysts, Canopy Growth Corporation (CGC) has a median price target of $1.81. The highest price target is $1.81 and the lowest is $1.81.
According to current analyst ratings, CGC has 1 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.02. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict CGC stock could reach $1.81 in the next 12 months. This represents a 77.2% increase from the current price of $1.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company generates revenue through the production, distribution, and sale of a wide range of cannabis products, including dried flower, extracts, edibles, and vaporizers. It operates in both the adult-use and medical cannabis markets, leveraging its strong presence in Canada and expanding into international markets such as Germany and Australia.
The highest price target for CGC is $1.81 from at , which represents a 77.2% increase from the current price of $1.02.
The lowest price target for CGC is $1.81 from at , which represents a 77.2% increase from the current price of $1.02.
The overall analyst consensus for CGC is neutral. Out of 9 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $1.81.
Stock price projections, including those for Canopy Growth Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.